Pfizer Deal Highlights Bristol's Biotech Swagger
Bristol-Myers' asset sale continued with a huge deal with Pfizer in April. The move demonstrates BMS' biotech-like strategy of monetizing late-stage assets to hedge risk.
Bristol-Myers' asset sale continued with a huge deal with Pfizer in April. The move demonstrates BMS' biotech-like strategy of monetizing late-stage assets to hedge risk.